Results 41 to 50 of about 178,848,266 (217)

Medication-related osteonecrosis of the jaw, a risk to reassess in osteoporotic patients

, 2023
INTRODUCTION: The use of antiresorptive drugs concerns many medical specialties either in relation to their prescription for osteoporosis or cancer, or in relation to the treatment of their side effects.
Magremanne, Michèle, Castiaux, Ludovic, Debiève, Maxime, van Maanen, Aline   +3 more
core   +1 more source

Platelet-rich fibrin treatment of medication-related osteonecrosis of the jaw followed up for two years [PDF]

, 2020
The use of platelet-rich fibrin (PRF) in surgery represents a new alternative method of treatment of Medication-related osteonecrosis of the jaws. This report presents a case of a patient undergoing PRF treatment.
Hristamyan, Meri; Department of Epidemiology and Disaster Medicine, Faculty of Public Health, Medical University-Plovidv, Hristamyan, Veselka; Clinic of Maxillofacial Surgery, St George University Hospital, Plovdiv   +1 more
core   +1 more source

Treatment protocols for the medication-related osteonecrosis of the jaw [PDF]

, 2017
Povećanjem broja pacijenata koji primaju antiresoptivnu ili antiangiogenu terapiju, doktori dentalne medicine se sve češće susreću s medikamentoznom osteonekrozom čeljusti.
Ivković, Tena
core   +1 more source

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Frontiers in Oral Health
IntroductionMedication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone.
Rodolfo Mauceri, Rodolfo Mauceri, Sonia Arduini, Martina Coppini, Martina Coppini, Martina Coppini, Monica Bazzano, Isabel Trujillo, Giuseppina Campisi   +8 more
doaj   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

The Effects of Simulation‐Based Interprofessional Education on Oncology Oral Care Competencies Among Dental and Dental Hygiene Students

European Journal of Dental Education, EarlyView.
ABSTRACT Introduction This study applied simulation‐based interprofessional education (IPE) principles to develop an oncology oral care scenario, with the aim of evaluating the intervention's effects on the IPE core competencies of dental and dental hygiene students before their clinical internships. Materials and Methods Twenty‐eight fifth‐year dental
Shin‐Ru Liao, Pei‐Chen Lin, Ai‐Hua Chang, Kun‐Tsung Lee, Peih‐Ying Lu, Hsiao‐Ling Huang, Ju‐Hui Wu   +6 more
wiley   +1 more source

Insufficient Evidence to Compare the Efficacy of Treatments for Medication-Related Osteonecrosis of the Jaws

, 2018
Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A.
McGowan, Kelly, Kelly McGowan
core   +1 more source

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review

Journal of Research in Medical Sciences, 2021
Medication related osteonecrosis of the jaw (MRONJ) is a severe condition affecting the jaws of patients exposed to specific drugs, and is primarily described in patients receiving bisphosphonate (BP) therapy.
Roberto Sacco, Julian Woolley, Julian Yates, Monica Diuana Calasans-Maia, Oladapo Akintola, Vinod Patel   +5 more
doaj   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

Internal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source